CagriSema is a combination of cagrilintide and semaglutide. A result for that combination cannot be assigned to cagrilintide alone. REDEFINE 2 helps show both the benefits observed and the limits of what a combination trial can answer.
The people and the comparison
This phase 3a trial randomized 1,206 adults with overweight or obesity and type 2 diabetes. There were 904 participants in the combination group and 302 in the placebo group. Both groups received lifestyle intervention, and the study lasted 68 weeks.
The main numbers
Estimated mean body-weight change was -13.7% with cagrilintide-semaglutide and -3.4% with placebo. The paper reported an estimated between-group difference of -10.4 percentage points; the displayed group means are rounded. HbA1c of 6.5% or less was reached by 73.5% and 15.9%, respectively. These are trial-group estimates, not a guarantee for an individual.
Why the trial population matters
People with type 2 diabetes differ from people without it in important ways. Comparing this headline weight result with another trial that enrolled a different population does not produce a fair ranking of products. Duration, background treatment and the statistical approach can also change the numbers.
Combination results and adverse events
Gastrointestinal adverse events were reported by 72.5% of the combination group and 34.4% of placebo recipients, mostly transient and mild or moderate. The trial does not isolate the contribution of each component. It also does not validate any catalogue blend’s ratio, stability or equivalence to the study formulation. A research enquiry should state each component and the required characterization separately.
Related materials and next steps
Explore the NHD catalogue records for Cagrilintide, Cagrilintide + Semaglutide Blend. Confirm the required molecular form, quantity and lot-document availability before relying on a listing for procurement. A catalogue record does not establish equivalence to a published study material.
Send the product or sequence, quantity and document requirements. For more background, browse the analytical methods guides and research glossary.
Sources and reading scope
Source links checked 5 October 2026. Research summaries use the accessible original abstract unless a full-text source is explicitly identified. Guidance documents and external supplier explanations are technical references, not NHD batch evidence or a claim of regulatory compliance. Any example introduced as hypothetical or teaching is a calculation, not a measured product result.
NHD catalogue materials are for qualified laboratory research, development and manufacturing enquiries. This article does not provide instructions for human or veterinary use.
Sources & editorial method
AI-assisted writing and source checks; conceptual illustrated cover.
1 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Study results and labeled examples are separated. Original-source, arithmetic, readability and internal-link checks; no independent human peer review recorded.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- REDEFINE 2: cagrilintide-semaglutide in adults with type 2 diabetesChecked 2026-10-05; source scope is identified in the article.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
